Shore Capital reiterated their hold rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report report published on Thursday, StockTargetPrices.com reports.

Several other equities research analysts have also recently issued reports on GSK. BNP Paribas cut GlaxoSmithKline plc to an underperform rating and set a GBX 1,520 ($18.48) target price for the company. in a research note on Wednesday, September 14th. Societe Generale reaffirmed a sell rating and issued a GBX 1,320 ($16.05) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, September 14th. J P Morgan Chase & Co reaffirmed a neutral rating on shares of GlaxoSmithKline plc in a research note on Friday, September 16th. Beaufort Securities reaffirmed a buy rating on shares of GlaxoSmithKline plc in a research note on Friday, September 16th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a buy rating and issued a GBX 1,800 ($21.89) price objective on shares of GlaxoSmithKline plc in a research note on Tuesday, September 20th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of GBX 1,723.91 ($20.96).

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Shares of GlaxoSmithKline plc (LON:GSK) traded up 1.25% on Thursday, reaching GBX 1585.50. The company had a trading volume of 7,713,896 shares. GlaxoSmithKline plc has a 52 week low of GBX 1,314.26 and a 52 week high of GBX 1,745.56. The company has a 50 day moving average of GBX 1,520.28 and a 200-day moving average of GBX 1,603.30. The company’s market capitalization is GBX 77.15 billion.

ILLEGAL ACTIVITY WARNING: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The original version of this news story can be read at http://www.watchlistnews.com/glaxosmithkline-plc-gsk-given-hold-rating-at-shore-capital/1060351.html.

The company also recently declared a dividend, which was paid on Thursday, January 12th. Stockholders of record on Thursday, November 3rd were paid a dividend of GBX 19 ($0.23) per share. This represents a dividend yield of 1.17%. The ex-dividend date was Thursday, November 3rd.

In related news, insider Sir Andrew P. Witty sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of GBX 1,636 ($19.90), for a total value of £163,600 ($198,954.15). Also, insider Manvinder Singh Banga bought 1,750 shares of GlaxoSmithKline plc stock in a transaction that occurred on Wednesday, October 26th. The stock was bought at an average cost of GBX 1,643 ($19.98) per share, for a total transaction of £28,752.50 ($34,965.95).

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Stock Target Prices

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.